Business
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb® PRINCETON, N.J., June 1, 2022 /PRNewswire/ --
About this update from Cytosorbents Corporation
[{"type":"text","content":"Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb®\nPRINCETON, N.J., June 1, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that following a successful pilot program in three countries, the Company has signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (Nikkiso) to distribute their PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries.\n\n \n \n \n \n \n \n\n \nCytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 CountriesIn addition to securing the rights to sell Nikkiso's stand-alone pump and accessories in Germany, Austria, and Luxembourg, CytoSorbents has entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzogovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. CytoSorbents will also be able to provide field support services in these countries.\nMr. Yoji Wakabayashi, Chief Executive Officer of Nikkiso Europe GmbH commented, \"We are pleased to partner with CytoSorbents to make our PureADJUST equipment and full range of consumables and accessories available to CytoSorbents' customers in these additional countries. PureADJUST's compact design, intuitive interface, and easy adsorber set up is the ideal solution to provide an additional platform to deliver CytoSorbents' industry-leading blood purification technology. We look forward to collaborating with CytoSorbents and growing our business worldwide together.\"\nDr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents added, \"This new business model unlocks a significant opportunity for us to increase CytoSorb usage. Today, it is very easy to start CytoSorb on critically ill patients who have developed kidney failure and are already on dialysis or continuous renal replacement therapy (CRRT). However, this accounts for only about 10% of patients in the ICU, where kidney failure often occurs late in the critical illness, resulting in delayed intervention with CytoSor...